Indications for RotaTeq

RotaTeq is an oral vaccine that can help protect against rotavirus gastroenteritis (RGE), a potentially serious and unpredictable disease.^3,6

RotaTeq is indicated for the prevention of RGE in infants and children caused by the serotypes G1, G2, G3, and G4 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks.

The first dose of RotaTeq should be administered between 6 and 12
weeks of age.

> Learn more about the dosage and administration for RotaTeq

Select safety information

RotaTeq should not be administered to infants with a demonstrated history of hypersensitivity to the vaccine or any component of the vaccine.

No safety or efficacy data are available for the administration of RotaTeq to infants who are potentially immunocompromised or to infants with a history of gastrointestinal disorders.

Caution is advised when considering whether to administer RotaTeq to individuals with immunodeficient contacts.

In clinical trials, the most common adverse events included diarrhea, vomiting, irritability, otitis media, nasopharyngitis, and bronchospasm.

In post-marketing experience, cases of intussusception and Kawasaki disease have been reported in infants who have received RotaTeq.

RotaTeq may not protect all vaccine recipients against rotavirus.

Before administering RotaTeq, please read the Prescribing Information and Patient Product Information.

RotaTeq is a registered trademark of Merck & Co., Inc.